Navigation Links
Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Date:7/29/2008

a, beta and gamma (IC50 >100 micrometers), demonstrating selectivity for the HCV 1a and 1b polymerases. After oral administration in monkeys, bioavailability of IDX375 was approximately 30%. Based on monkey plasma drug exposure levels, IDX375 has the potential for once-daily dosing in man.

IDX136 and IDX316 Macrocyclic Protease Inhibitors

Idenix has scaled up manufacturing of two clinical candidates, IDX136 and IDX316, from its HCV protease inhibitor discovery program to support IND-enabling pharmacology and toxicology studies. Both IDX136 and IDX316 are based on Idenix's proprietary scaffold B and were developed through SAR (structural activity relationship) approaches aided by high-resolution co-crystal structures with the HCV protease. IDX136 and IDX316 have demonstrated single nanomolar potency against HCV genotype 1a and 1b purified proteases and nanomolar potency against HCV genotype 1b replicon (EC50 = 4 to 10 nM). Additionally, these compounds are highly selective, binding tightly to the HCV protease and demonstrating no activity against eight human cellular proteases. Both drug candidates appear to have a differentiated resistance profile when compared to other macrocyclic protease inhibitors in development. Favorable pharmacokinetic properties of IDX136 and IDX316 in non-human primates suggest the potential for once- or twice-daily dosing in man.

Conference Call Information

Idenix will hold a conference call and webcast today at 8:30 a.m. ET. To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 56201724 or to listen to and view the live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. A replay of the call will also be available from 11:30 a.m. ET on July 29, 2008 until 11:59 p.m. ET on August 12, 2008. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-929
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
4. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
6. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
7. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
8. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
9. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
10. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
11. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 ... Nitrate Industry" and "2014 Deep Research Report on ... to its research database. Photo ... Deep Research Report on Global and China Potassium ... report on China and ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2
... 1, 2011    Advanced Biologics, ( www.advancedbiologics.com ) ... newest product within the OsteoAMP ® platform ... meeting this week in Chicago, IL.  OsteoAMP Structural ... that demonstrates osteoinductive properties in-vivo.  Initial product offerings ...
... 2011 Merz Aesthetics, Inc., the exclusive distributor of ... launch of the "STAND AND DELIVER" program.  In partnership ... selected for their significant abilities to STAND AND DELIVER, ... a stand by making a difference in their communities. ...
Cached Medicine Technology:Advanced Biologics Launches OsteoAMP® Structural at the 26th Annual Meeting of the North American Spine Society 2Merz Aesthetics and Inspirational Women Join Forces to Recognize Women Who STAND AND DELIVER 2Merz Aesthetics and Inspirational Women Join Forces to Recognize Women Who STAND AND DELIVER 3
(Date:8/2/2014)... Arizona (PRWEB) August 02, 2014 ... the nation's number one provider of customized medical and ... two major dental-industry conferences this fall. CEDR’s CEO will ... in September and early December. , From September 4-6, ... Dental Office Managers (AADOM) Dental Managers Conference in San ...
(Date:8/1/2014)... 02, 2014 Recently, iFitDress.com, one of the ... new assortment of top bridesmaid dresses online. At ... promotional prices, up to 52% off. According to the company’s ... of August. , The company’s stock is limited. Those ... its online store as soon as possible. All its products ...
(Date:8/1/2014)... University School of Medicine in St. Louis helps explain ... frequently are more harmful than similar tumors in females. ... are diagnosed twice as often in males, who suffer ... as long. , The researchers found that retinoblastoma protein ... significantly less active in male brain cells than in ...
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ) filed in the wake of the 2012 ... continue to move forward in New Jersey’s Bergen ... to documents filed in the proceeding, the Court ... Order of Confidentiality governing any and all hard ...
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4
... of Houston (UH) has invited best-selling author and noted physician ... in Family, Health and Human Values at 7:30 p.m., Monday, ... "As an Indian-American immigrant to the United States, Dr. ... inaugurate the new India studies program at UH," said Lois ...
... A UCSF study gives hope to those suffering from severe ... if left untreated. The use of topical corticosteroids in a ... harmful in the overall patient population in the study. However, ... corneal ulcers, according to UCSF researchers. In a paper ...
... , TUESDAY, Oct. 18 (HealthDay News) -- Colorectal cancers ... the cancer and could prove important in diagnosing, treating and ... the Dana-Farber Cancer Institute and the Broad Institute in Boston ... of colorectal cancer tissue and found unusually high numbers of ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay News) ... Pap tests as a cervical cancer screening tool among ... The U.S. Preventive Services Task Force published ... are now seeking to fine-tune these guidelines. The results ...
... -- Unstructured play is much better than TV or videos ... American Academy of Pediatrics policy statement says. Free play ... solve, and develop reasoning and motor skills at an early ... pediatric experts pointed out in an AAP news release. ...
... has found that coughing may signal trouble for patients with ... published in the journal Respirology , found that patients ... develop advanced forms of the disease that may be life ... the lungs becomes thick and scarred, likely due to a ...
Cached Medicine News:Health News:Dr. Abraham Verghese to give John P. McGovern Lecture on Oct. 24 2Health News:UCSF study finds steroids could help heal some corneal ulcers 2Health News:Link Explored Between Colon Cancer, Bacterium 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 3Health News:'Screen-Free' Play Best for Toddlers' Brains 2Health News:Cough may warn of danger for patients with lung-scarring disease 2
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Plastic Tray Type Vacuum Manifold...
... manifold is designed to efficiently process ... holds one deep well plate and ... are drawn through the wells ... microplates. The base holds and ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Medicine Products: